| Over a week ago | ||||
Lake Street analyst… Lake Street analyst Brooks O'Neil raised the firm's price target on Semler Scientific to $100 from $75 and keeps a Buy rating on the shares after the company "delivered Q3 results which blew our mind." Revenue beat his forecast by about 24%, while EPS beat his forecast by 177%, O'Neil said. Two customers accounted for 69% of revenue, which might worry some investors, but he thinks it should not given that both "are large, growing, stable and happy customers" and "there are literally hundreds more potential customers for Semler's existing product," the analyst tells investors. | ||||
| Over a quarter ago | ||||
Virtual Meeting to be… Virtual Meeting to be held on August 27 hosted by B. Riley FBR. | ||||
Virtual Meeting to be… Virtual Meeting to be held on August 27 hosted by B. Riley FBR. | ||||
Semler Scientific… Semler Scientific announced the appointment of Daniel Messina to its Board of Directors, effective August 13, 2020. With this addition, Semler's Board now totals four members. Messina is the co-founder of HandsFree Health, the creator of WellBe, the premier voice enabled virtual health assistant platform designed to help individuals access their health and wellness resources from home. | ||||
B. Riley FBR analyst Josh… B. Riley FBR analyst Josh Nichols initiated coverage of Semler Scientific with a Buy rating and $61 price target. The company's patented QuantaFlo product, which acts as an early detection test for peripheral arterial disease, has seen a significant increase in usage and a growing installed base since gaining FDA approval in March 2015, Nichols tells investors in a research note. While Semler is "significantly profitable" with 35%-plus EBITDA margins and 89% sales growth in 2019, the company has "flown under the radar," in part due to its smaller size and over-the-counter listing, adds the analyst. Nichols views the shares as "materially undervalued." | ||||